vorinostat has been researched along with Cancer of Prostate in 56 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Vorinostat is an inhibitor of histone deacetylase 6, which acetylates tubulin and stabilizes microtubules." | 2.77 | Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies. ( Bradley, D; Daignault, S; Dunn, R; Egorin, MJ; Hussain, M; Kalemkerian, GP; Schneider, BJ; Smith, DC, 2012) |
| "Vorinostat at this dose was associated with significant toxicities limiting efficacy assessment in this patient population." | 2.74 | Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and Universi ( Bradley, D; Dunn, R; Hussain, M; Liu, G; Pili, R; Rathkopf, D; Scher, H; Smith, DC; Stadler, WM; Zwiebel, J, 2009) |
| "Castration-resistant prostate cancer (PCa) represents a serious health challenge." | 1.51 | Targeting genotoxic and proteotoxic stress-response pathways in human prostate cancer by clinically available PARP inhibitors, vorinostat and disulfiram. ( Bartek, J; Bartkova, J; Bouchal, J; Cwiertka, K; Gachechiladze, M; Gursky, J; Hodny, Z; Korinkova, G; Kurfurstova, D; Majera, D; Mistrik, M; Simkova, D; Skrott, Z; Steigerova, J, 2019) |
| "AKR1C3 protein is elevated within prostate cancer tissue, it contributes to the formation of androgens and downstream stimulation of the androgen receptor (AR)." | 1.43 | Knockdown of AKR1C3 exposes a potential epigenetic susceptibility in prostate cancer cells. ( Battaglia, S; Bunce, CM; Campbell, MJ; Doig, CL; Khanim, FL, 2016) |
| "Pretreatment with vorinostat led to radiosensitisation of the intrinsically radioresistant DU 145 cells, but not the radiosensitive PC-3 and 22Rv1 cells, and was independent of hypoxia status." | 1.43 | Hypoxia-independent gene expression signature associated with radiosensitisation of prostate cancer cell lines by histone deacetylase inhibition. ( Clancy, T; Flatmark, K; Frikstad, KM; Jonsson, M; Julin, CH; Lyng, H; Matias-Guiu, X; Ragnum, HB; Ree, AH; Seierstad, T; Stokke, T; Yeramian, A, 2016) |
| "Paclitaxel (PTX) is a microtubule-targeting drug widely used for the treatment of a variety of cancers." | 1.43 | Mechanism of paclitaxel resistance in a human prostate cancer cell line, PC3-PR, and its sensitization by cabazitaxel. ( Aoyama, Y; Ichihara, M; Kawamoto, Y; Mizutani, N; Murate, T; Nozawa, Y; Sobue, S; Suzuki, M, 2016) |
| "In this study, using the prostate cancer cell line PC3 and the non-small lung cancer cell line A549, which have limited sensitivity to SAHA, we found that SAHA triggered MET and AKT phosphorylation at clinical concentrations." | 1.42 | SAHA triggered MET activation contributes to SAHA tolerance in solid cancer cells. ( Ding, L; Liang, G; Tariq, M; Wang, B; Wu, H; Yang, B; Yao, Z; Ying, M; Zhang, J; Zhang, Z, 2015) |
| "A transcriptome analysis in prostate cancer PC3 cells identified a subset of NF-κB target genes reversibly regulated by vorinostat, as well as a group of interferon (IFN)-stimulated genes (ISGs)." | 1.40 | Histone deacetylase inhibitors potentiate vesicular stomatitis virus oncolysis in prostate cancer cells by modulating NF-κB-dependent autophagy. ( Belgnaoui, SM; Beljanski, V; Chiang, C; Di Lenardo, T; Dutta, SM; Hiscott, J; Lin, R; Nguyên, TL; Semmes, OJ; Shulak, L; Van Grevenynghe, J, 2014) |
| "Vorinostat, which is an extensively studied inhibitor against histone deacetylase (HDAC), shows limited clinical activity to solid tumors." | 1.40 | A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I. ( Chao, SW; Guh, JH; Hsu, JL; Huang, WJ; Li, TK; Liu, SP; Pan, SL; Yang, YC; Yu, CC, 2014) |
| "Silencing RAD51 sensitized prostate cancer cells to SAHA and olaparib alone." | 1.40 | Synergistic loss of prostate cancer cell viability by coinhibition of HDAC and PARP. ( Chao, OS; Goodman, OB, 2014) |
| " This study investigated the effects of complexing iron (Fe3+) to the HDACi suberoylanilide hydroxamic acid (SAHA) and LAQ824 (LAQ) prior to their encapsulation into PEGylated liposomes, and investigated whether this technique could improve drug solubility, in vitro release and in vivo pharmacokinetic (PK) properties." | 1.40 | Iron complexation to histone deacetylase inhibitors SAHA and LAQ824 in PEGylated liposomes can considerably improve pharmacokinetics in rats. ( Steffen, D; Tu, S; Wang, Y; Xiong, M, 2014) |
| "Moreover, the highly metastatic prostate cancer PC3 cells were also sensitive to (S)-2 that: i) induced growth arrest and moderate apoptosis; ii) steered cells towards differentiation and neutral lipid accumulation; iii) reduced cell invasiveness potential by decreasing the amount of MMP-9 activity and up-regulating TIMP-1 expression; and iv) inhibited cell motility and migration through the Matrigel." | 1.39 | Effectiveness of the histone deacetylase inhibitor (S)-2 against LNCaP and PC3 human prostate cancer cells. ( Balliu, M; Cellai, C; Laurenzana, A; Paoletti, F; Romanelli, MN, 2013) |
| " Therefore, we studied the effect of polo-like kinase 1 (Plk1) inhibitors on prostate cancer cells as a single agent and in combination with histone deacetylase (HDAC) inhibitors valproic acid and vorinostat." | 1.39 | Targeting prostate cancer cell lines with polo-like kinase 1 inhibitors as a single agent and in combination with histone deacetylase inhibitors. ( Carducci, MA; Gonzalez, M; Hammers, H; Kachhap, SK; Kaelber, NS; Kim, E; Kortenhorst, MS; Mendonca, J; van Diest, PJ; Wissing, MD, 2013) |
| "Genistein is a soy isoflavone with diverse effects on cellular proliferation, survival, and gene expression that suggest it could be a potential therapeutic agent for prostate cancer." | 1.38 | Genistein cooperates with the histone deacetylase inhibitor vorinostat to induce cell death in prostate cancer cells. ( Bilir, B; Cutler, DJ; Giardina, CK; Kucuk, O; Lai, YH; Moreno, CS; Phillip, CJ, 2012) |
| "Most prostate, colon and breast cancer cells are resistant to growth inhibitory effects of suberoylanilide hydroxamic acid (SAHA)." | 1.37 | Pretreatment with anti-oxidants sensitizes oxidatively stressed human cancer cells to growth inhibitory effect of suberoylanilide hydroxamic acid (SAHA). ( Basu, HS; Guo, S; Kegel, SJ; Mahlum, A; Mehraein-Ghomi, F; Peters, NR; Wilding, G, 2011) |
| "Progression of prostate cancer following castration is associated with increased androgen receptor (AR) expression and signaling despite AR blockade." | 1.36 | Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. ( Coleman, IM; Haugk, K; Mostaghel, EA; Nelson, PS; Nguyen, HM; Page, ST; Plymate, SR; Soriano, K; Sprenger, CC; Sun, H; Sun, S; Vessella, RL, 2010) |
| " These results demonstrate that compound 2 and its combination with SAHA are potentially useful agents that warrant further preclinical development for treatment of prostate cancer." | 1.35 | Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts. ( Belosay, A; Gediya, LK; Khandelwal, A; Njar, VC; Purushottamachar, P, 2008) |
| "Growth of prostate cancer cells is initially dependent on androgens, and androgen ablation therapy is used to control tumor growth." | 1.34 | Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation. ( Bianco-Miotto, T; Butler, LM; Evdokiou, A; Marks, PA; Marrocco, DL; Richon, VM; Rifkind, RA; Scher, HI; Tilley, WD, 2007) |
| "(S)-HDAC-42 is a potent orally bioavailable inhibitor of HDAC, as well as targets regulating multiple aspects of cancer cell survival, which might have clinical value in prostate cancer chemotherapy and warrants further investigation in this regard." | 1.33 | Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer. ( Chen, CS; Chen, CY; Kulp, SK; Wang, DS, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.79) | 18.2507 |
| 2000's | 17 (30.36) | 29.6817 |
| 2010's | 38 (67.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Stowell, JC | 1 |
| Huot, RI | 1 |
| Van Voast, L | 1 |
| Wang, DF | 1 |
| Wiest, O | 1 |
| Helquist, P | 1 |
| Lan-Hargest, HY | 1 |
| Wiech, NL | 1 |
| Gediya, LK | 2 |
| Chopra, P | 1 |
| Purushottamachar, P | 2 |
| Maheshwari, N | 1 |
| Njar, VC | 2 |
| Belosay, A | 1 |
| Khandelwal, A | 1 |
| Yao, Y | 1 |
| Tu, Z | 1 |
| Liao, C | 1 |
| Wang, Z | 1 |
| Li, S | 1 |
| Yao, H | 1 |
| Li, Z | 1 |
| Jiang, S | 1 |
| Jadhavar, PS | 1 |
| Ramachandran, SA | 1 |
| Riquelme, E | 1 |
| Gupta, A | 2 |
| Quinn, KP | 1 |
| Shivakumar, D | 1 |
| Ray, S | 1 |
| Zende, D | 1 |
| Nayak, AK | 1 |
| Miglani, SK | 1 |
| Sathe, BD | 1 |
| Raja, M | 1 |
| Farias, O | 1 |
| Alfaro, I | 1 |
| Belmar, S | 1 |
| Guerrero, J | 1 |
| Bernales, S | 1 |
| Chakravarty, S | 1 |
| Hung, DT | 1 |
| Lindquist, JN | 1 |
| Rai, R | 1 |
| Lee, HY | 1 |
| Lee, JF | 1 |
| Kumar, S | 1 |
| Wu, YW | 2 |
| HuangFu, WC | 1 |
| Lai, MJ | 1 |
| Li, YH | 1 |
| Huang, HL | 2 |
| Kuo, FC | 1 |
| Hsiao, CJ | 1 |
| Cheng, CC | 1 |
| Yang, CR | 1 |
| Liou, JP | 2 |
| Mehndiratta, S | 1 |
| Wang, RS | 1 |
| Su, CJ | 1 |
| Hsu, CM | 1 |
| Pan, SL | 2 |
| Li, X | 2 |
| Peterson, YK | 1 |
| Inks, ES | 1 |
| Himes, RA | 1 |
| Li, J | 1 |
| Zhang, Y | 1 |
| Kong, X | 1 |
| Chou, CJ | 1 |
| Butt, NA | 1 |
| Kumar, A | 1 |
| Dhar, S | 1 |
| Rimando, AM | 1 |
| Akhtar, I | 1 |
| Hancock, JC | 1 |
| Lage, JM | 1 |
| Pound, CR | 1 |
| Lewin, JR | 1 |
| Gomez, CR | 1 |
| Levenson, AS | 1 |
| Shi, XY | 1 |
| Ding, W | 1 |
| Li, TQ | 1 |
| Zhang, YX | 1 |
| Zhao, SC | 1 |
| Jang, YG | 1 |
| Hwang, KA | 1 |
| Choi, KC | 1 |
| Majera, D | 1 |
| Skrott, Z | 1 |
| Bouchal, J | 1 |
| Bartkova, J | 1 |
| Simkova, D | 1 |
| Gachechiladze, M | 1 |
| Steigerova, J | 1 |
| Kurfurstova, D | 1 |
| Gursky, J | 1 |
| Korinkova, G | 1 |
| Cwiertka, K | 1 |
| Hodny, Z | 1 |
| Mistrik, M | 1 |
| Bartek, J | 1 |
| Natarajan, U | 1 |
| Venkatesan, T | 1 |
| Radhakrishnan, V | 1 |
| Samuel, S | 1 |
| Rasappan, P | 1 |
| Rathinavelu, A | 1 |
| Ishigami-Yuasa, M | 1 |
| Ekimoto, H | 1 |
| Kagechika, H | 1 |
| Chachadi, VB | 1 |
| Ali, MF | 1 |
| Cheng, PW | 1 |
| Laurenzana, A | 1 |
| Balliu, M | 1 |
| Cellai, C | 1 |
| Romanelli, MN | 1 |
| Paoletti, F | 1 |
| Patra, N | 1 |
| De, U | 1 |
| Kim, TH | 1 |
| Lee, YJ | 1 |
| Ahn, MY | 1 |
| Kim, ND | 1 |
| Yoon, JH | 1 |
| Choi, WS | 1 |
| Moon, HR | 1 |
| Lee, BM | 1 |
| Kim, HS | 1 |
| Kortenhorst, MS | 3 |
| Wissing, MD | 2 |
| Rodríguez, R | 1 |
| Kachhap, SK | 2 |
| Jans, JJ | 1 |
| Van der Groep, P | 1 |
| Verheul, HM | 2 |
| Aiyetan, PO | 1 |
| van der Wall, E | 1 |
| Carducci, MA | 3 |
| Van Diest, PJ | 2 |
| Marchionni, L | 1 |
| Mendonca, J | 1 |
| Kaelber, NS | 1 |
| Gonzalez, M | 1 |
| Kim, E | 1 |
| Hammers, H | 1 |
| Shulak, L | 1 |
| Beljanski, V | 1 |
| Chiang, C | 1 |
| Dutta, SM | 1 |
| Van Grevenynghe, J | 1 |
| Belgnaoui, SM | 1 |
| Nguyên, TL | 1 |
| Di Lenardo, T | 1 |
| Semmes, OJ | 1 |
| Lin, R | 1 |
| Hiscott, J | 1 |
| Yu, CC | 1 |
| Chao, SW | 1 |
| Liu, SP | 1 |
| Hsu, JL | 1 |
| Yang, YC | 1 |
| Li, TK | 1 |
| Huang, WJ | 1 |
| Guh, JH | 1 |
| Rich, A | 1 |
| Sun, J | 1 |
| Aldayel, AS | 1 |
| Yin, CC | 1 |
| Medeiros, LJ | 1 |
| Konoplev, S | 1 |
| Chao, OS | 1 |
| Goodman, OB | 1 |
| Ding, L | 1 |
| Zhang, Z | 1 |
| Liang, G | 1 |
| Yao, Z | 1 |
| Wu, H | 1 |
| Wang, B | 1 |
| Zhang, J | 1 |
| Tariq, M | 1 |
| Ying, M | 1 |
| Yang, B | 1 |
| Wang, Y | 1 |
| Tu, S | 1 |
| Steffen, D | 1 |
| Xiong, M | 1 |
| Doig, CL | 1 |
| Battaglia, S | 1 |
| Khanim, FL | 1 |
| Bunce, CM | 1 |
| Campbell, MJ | 1 |
| Gameiro, SR | 1 |
| Malamas, AS | 1 |
| Tsang, KY | 1 |
| Ferrone, S | 1 |
| Hodge, JW | 1 |
| Carter, SL | 2 |
| Centenera, MM | 2 |
| Tilley, WD | 3 |
| Selth, LA | 2 |
| Butler, LM | 4 |
| Rosati, R | 1 |
| Chen, B | 1 |
| Patki, M | 1 |
| McFall, T | 1 |
| Ou, S | 1 |
| Heath, E | 2 |
| Ratnam, M | 1 |
| Qin, Z | 1 |
| Jonsson, M | 1 |
| Ragnum, HB | 1 |
| Julin, CH | 1 |
| Yeramian, A | 1 |
| Clancy, T | 1 |
| Frikstad, KM | 1 |
| Seierstad, T | 1 |
| Stokke, T | 1 |
| Matias-Guiu, X | 1 |
| Ree, AH | 1 |
| Flatmark, K | 1 |
| Lyng, H | 1 |
| Sobue, S | 1 |
| Mizutani, N | 1 |
| Aoyama, Y | 1 |
| Kawamoto, Y | 1 |
| Suzuki, M | 1 |
| Nozawa, Y | 1 |
| Ichihara, M | 1 |
| Murate, T | 1 |
| Thapa, RK | 1 |
| Nguyen, HT | 1 |
| Jeong, JH | 1 |
| Shin, BS | 1 |
| Ku, SK | 1 |
| Choi, HG | 1 |
| Yong, CS | 1 |
| Kim, JO | 1 |
| Chen, G | 1 |
| Li, A | 1 |
| Zhao, M | 1 |
| Gao, Y | 1 |
| Zhou, T | 1 |
| Xu, Y | 1 |
| Du, Z | 1 |
| Zhang, X | 1 |
| Yu, X | 1 |
| Schmudde, M | 1 |
| Braun, A | 1 |
| Pende, D | 1 |
| Sonnemann, J | 3 |
| Klier, U | 1 |
| Beck, JF | 3 |
| Moretta, L | 1 |
| Bröker, BM | 1 |
| Zahurak, M | 1 |
| Shabbeer, S | 1 |
| Kachhap, S | 1 |
| Galloway, N | 1 |
| Parmigiani, G | 1 |
| Bradley, D | 2 |
| Rathkopf, D | 1 |
| Dunn, R | 2 |
| Stadler, WM | 1 |
| Liu, G | 1 |
| Smith, DC | 2 |
| Pili, R | 1 |
| Zwiebel, J | 1 |
| Scher, H | 1 |
| Hussain, M | 2 |
| Zhou, X | 2 |
| Yang, XY | 2 |
| Popescu, NC | 2 |
| Basu, HS | 1 |
| Mahlum, A | 1 |
| Mehraein-Ghomi, F | 1 |
| Kegel, SJ | 1 |
| Guo, S | 1 |
| Peters, NR | 1 |
| Wilding, G | 1 |
| Sun, S | 1 |
| Sprenger, CC | 1 |
| Vessella, RL | 1 |
| Haugk, K | 1 |
| Soriano, K | 1 |
| Mostaghel, EA | 1 |
| Page, ST | 1 |
| Coleman, IM | 1 |
| Nguyen, HM | 1 |
| Sun, H | 1 |
| Nelson, PS | 1 |
| Plymate, SR | 1 |
| Schneider, BJ | 1 |
| Kalemkerian, GP | 1 |
| Egorin, MJ | 1 |
| Daignault, S | 1 |
| Kaplun, A | 1 |
| Lonardo, F | 1 |
| Sarkar, FH | 1 |
| Irish, J | 1 |
| Sakr, W | 1 |
| Sheng, S | 1 |
| Zeglis, BM | 1 |
| Pillarsetty, N | 1 |
| Divilov, V | 1 |
| Blasberg, RA | 1 |
| Lewis, JS | 1 |
| Phillip, CJ | 1 |
| Giardina, CK | 1 |
| Bilir, B | 1 |
| Cutler, DJ | 1 |
| Lai, YH | 1 |
| Kucuk, O | 1 |
| Moreno, CS | 1 |
| Sato, A | 1 |
| Asano, T | 2 |
| Ito, K | 1 |
| Gänge, J | 1 |
| Kumar, KS | 1 |
| Müller, C | 1 |
| Bader, P | 1 |
| Chinnaiyan, P | 1 |
| Vallabhaneni, G | 1 |
| Armstrong, E | 1 |
| Huang, SM | 1 |
| Harari, PM | 1 |
| Lakshmikanthan, V | 1 |
| Kaddour-Djebbar, I | 1 |
| Lewis, RW | 1 |
| Kumar, MV | 1 |
| Kulp, SK | 2 |
| Chen, CS | 3 |
| Wang, DS | 1 |
| Chen, CY | 1 |
| Xu, W | 1 |
| Ngo, L | 1 |
| Perez, G | 1 |
| Dokmanovic, M | 1 |
| Marks, PA | 3 |
| Marrocco, DL | 1 |
| Bianco-Miotto, T | 1 |
| Evdokiou, A | 1 |
| Scher, HI | 2 |
| Rifkind, RA | 2 |
| Richon, VM | 2 |
| Bumbul, B | 1 |
| Sargeant, AM | 1 |
| Rengel, RC | 1 |
| Klein, RD | 1 |
| Clinton, SK | 1 |
| Wang, YC | 1 |
| Agus, DB | 1 |
| Higgins, B | 1 |
| Rose, A | 1 |
| Cordon-Cardo, C | 1 |
| Thaler, HT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Study of Entinostat in Combination With Enzalutamide for Treatment of Patients With Castration-Resistant Prostate Cancer[NCT03829930] | Phase 1 | 6 participants (Actual) | Interventional | 2019-05-01 | Terminated (stopped due to Sponsor discontinued the drug) | ||
| IGHID 11424 - A Pilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection (The VOR VAX Study)[NCT02707900] | Phase 1 | 6 participants (Actual) | Interventional | 2016-03-31 | Terminated (stopped due to Manufacturing of the AGS-004 HIV vaccine by Argos could no longer be provided.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for vorinostat and Cancer of Prostate
| Article | Year |
|---|---|
Myelomastocytic leukemia with aberrant CD25 expression: case report and review of the literature.
Topics: Adenocarcinoma; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumo | 2014 |
Histone deacetylase inhibitors interact synergistically with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to induce apoptosis in carcinoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Butyric Acid; Caspase 3; Caspases; | 2005 |
2 trials available for vorinostat and Cancer of Prostate
| Article | Year |
|---|---|
Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and Universi
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Drug Resistance, Neoplasm; Enz | 2009 |
Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Dru | 2012 |
52 other studies available for vorinostat and Cancer of Prostate
| Article | Year |
|---|---|
The synthesis of N-hydroxy-N'-phenyloctanediamide and its inhibitory effect on proliferation of AXC rat prostate cancer cells.
Topics: Amides; Animals; Antineoplastic Agents; Cell Division; Drug Screening Assays, Antitumor; Hydroxamic | 1995 |
QSAR studies of PC-3 cell line inhibition activity of TSA and SAHA-like hydroxamic acids.
Topics: Antineoplastic Agents; Cell Division; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Histone Dea | 2004 |
A new simple and high-yield synthesis of suberoylanilide hydroxamic acid and its inhibitory effect alone or in combination with retinoids on proliferation of human prostate cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Histone Deacetylase Inh | 2005 |
Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Cycle; Cell Differentiatio | 2008 |
Discovery of Novel Class I Histone Deacetylase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Chemistry Techniques, Synthetic; Depsipeptides; Dr | 2015 |
Targeting prostate cancer with compounds possessing dual activity as androgen receptor antagonists and HDAC6 inhibitors.
Topics: Androgen Antagonists; Animals; Cell Line, Tumor; Crystallography, X-Ray; Histone Deacetylase 6; Hist | 2016 |
3-Aroylindoles display antitumor activity in vitro and in vivo: Effects of N1-substituents on biological activity.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Design; HeLa Cells; Histone Deacetylase 6; Hi | 2017 |
4-Indolyl-N-hydroxyphenylacrylamides as potent HDAC class I and IIB inhibitors in vitro and in vivo.
Topics: Acrylamides; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Histone Deacetyla | 2017 |
Class I HDAC Inhibitors Display Different Antitumor Mechanism in Leukemia and Prostatic Cancer Cells Depending on Their p53 Status.
Topics: Antineoplastic Agents; Apoptosis; Caspase 3; CD13 Antigens; Cell Cycle Checkpoints; Cell Line, Tumor | 2018 |
Targeting MTA1/HIF-1α signaling by pterostilbene in combination with histone deacetylase inhibitor attenuates prostate cancer progression.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cell | 2017 |
Histone Deacetylase (HDAC) Inhibitor, Suberoylanilide Hydroxamic Acid (SAHA), Induces Apoptosis in Prostate Cancer Cell Lines via the Akt/FOXO3a Signaling Pathway.
Topics: Annexin A5; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell | 2017 |
Rosmarinic Acid, a Component of Rosemary Tea, Induced the Cell Cycle Arrest and Apoptosis through Modulation of HDAC2 Expression in Prostate Cancer Cell Lines.
Topics: Annexin A5; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Cell Cycle Checkpoints; Cell Line, Tum | 2018 |
Targeting genotoxic and proteotoxic stress-response pathways in human prostate cancer by clinically available PARP inhibitors, vorinostat and disulfiram.
Topics: Cell Line, Tumor; Disulfiram; DNA Repair; Gene Expression Regulation, Neoplastic; Humans; Male; Mole | 2019 |
Cell Cycle Arrest and Cytotoxic Effects of SAHA and RG7388 Mediated through p21
Topics: Apoptosis; Breast Neoplasms; Cell Cycle Checkpoints; Cell Survival; Cyclin-Dependent Kinase Inhibito | 2019 |
Class IIb HDAC Inhibition Enhances the Inhibitory Effect of Am80, a Synthetic Retinoid, in Prostate Cancer.
Topics: Antineoplastic Agents; Benzoates; Cell Line, Tumor; Decitabine; Drug Synergism; Drug Therapy, Combin | 2019 |
Prostatic cell-specific regulation of the synthesis of MUC1-associated sialyl Lewis a.
Topics: CA-19-9 Antigen; Cell Line; Glycoproteins; Glycosyltransferases; Histone Deacetylase Inhibitors; His | 2013 |
Effectiveness of the histone deacetylase inhibitor (S)-2 against LNCaP and PC3 human prostate cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caspases; Cell Cycle Checkpoints; Cell Line, Tumor; Cell | 2013 |
A novel histone deacetylase (HDAC) inhibitor MHY219 induces apoptosis via up-regulation of androgen receptor expression in human prostate cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Cycle; Cell Cycle Checkpoints; Cell Line, | 2013 |
Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors.
Topics: Cell Line, Tumor; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genome, Human; | 2013 |
Targeting prostate cancer cell lines with polo-like kinase 1 inhibitors as a single agent and in combination with histone deacetylase inhibitors.
Topics: Antineoplastic Agents; Cell Cycle Proteins; Cell Line, Tumor; Drug Therapy, Combination; Histone Dea | 2013 |
Histone deacetylase inhibitors potentiate vesicular stomatitis virus oncolysis in prostate cancer cells by modulating NF-κB-dependent autophagy.
Topics: Acetylation; Animals; Autophagy; Cell Line, Tumor; Chromatin; Cluster Analysis; Gene Knockdown Techn | 2014 |
A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
Topics: Acridines; Animals; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cells, Cultured; DNA Damage | 2014 |
Synergistic loss of prostate cancer cell viability by coinhibition of HDAC and PARP.
Topics: BRCA1 Protein; Cell Line, Tumor; Cell Survival; DNA Breaks, Double-Stranded; DNA Repair; Drug Synerg | 2014 |
SAHA triggered MET activation contributes to SAHA tolerance in solid cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Proliferation; Drug Resistance, N | 2015 |
Iron complexation to histone deacetylase inhibitors SAHA and LAQ824 in PEGylated liposomes can considerably improve pharmacokinetics in rats.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Cell Line, Tumor; Drug Liberation; Female; Half-Li | 2014 |
Knockdown of AKR1C3 exposes a potential epigenetic susceptibility in prostate cancer cells.
Topics: 3-Hydroxysteroid Dehydrogenases; Aldo-Keto Reductase Family 1 Member C3; Cell Line, Tumor; Cell Prol | 2016 |
Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells.
Topics: Apoptosis; Benzamides; Blotting, Western; Breast Neoplasms; Cell Proliferation; Female; Flow Cytomet | 2016 |
IκBα mediates prostate cancer cell death induced by combinatorial targeting of the androgen receptor.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2016 |
Hybrid Enzalutamide Derivatives with Histone Deacetylase Inhibitor Activity Decrease Heat Shock Protein 90 and Androgen Receptor Levels and Inhibit Viability in Enzalutamide-Resistant C4-2 Prostate Cancer Cells.
Topics: Acetylation; Benzamides; Cell Line, Tumor; Cell Nucleus; Cell Survival; Chromatin; Cyclin-Dependent | 2016 |
Hypoxia-independent gene expression signature associated with radiosensitisation of prostate cancer cell lines by histone deacetylase inhibition.
Topics: Adenocarcinoma; Antineoplastic Agents; Biomarkers, Tumor; Cell Cycle; Cell Hypoxia; Cell Line, Tumor | 2016 |
Mechanism of paclitaxel resistance in a human prostate cancer cell line, PC3-PR, and its sensitization by cabazitaxel.
Topics: Acetylation; Anilides; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Proliferation; Cycl | 2016 |
Synergistic anticancer activity of combined histone deacetylase and proteasomal inhibitor-loaded zein nanoparticles in metastatic prostate cancers.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bortezomi | 2017 |
Proteomic analysis identifies protein targets responsible for depsipeptide sensitivity in tumor cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Depsipeptides; DNA Damage; E | 2008 |
Histone deacetylase inhibitors sensitize tumour cells for cytotoxic effects of natural killer cells.
Topics: Antineoplastic Agents; Cell Death; Cell Line, Tumor; Cell Survival; Histone Deacetylase Inhibitors; | 2008 |
A multiple-loop, double-cube microarray design applied to prostate cancer cell lines with variable sensitivity to histone deacetylase inhibitors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gene Expressi | 2008 |
Synergistic antineoplastic effect of DLC1 tumor suppressor protein and histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), on prostate and liver cancer cells: perspectives for therapeutics.
Topics: Adenoviridae; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Shape; | 2010 |
Pretreatment with anti-oxidants sensitizes oxidatively stressed human cancer cells to growth inhibitory effect of suberoylanilide hydroxamic acid (SAHA).
Topics: Antioxidants; Breast Neoplasms; Cell Line, Tumor; Chromatography, Liquid; Colonic Neoplasms; Drug Re | 2011 |
Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant.
Topics: Androgen Antagonists; Animals; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Hyd | 2010 |
HDAC1 inhibition by maspin abrogates epigenetic silencing of glutathione S-transferase pi in prostate carcinoma cells.
Topics: Carcinoma; Cell Line, Tumor; Cell Survival; Gene Silencing; Glutathione S-Transferase pi; Histone De | 2011 |
The synthesis and evaluation of N1-(4-(2-[18F]-fluoroethyl)phenyl)-N8-hydroxyoctanediamide ([18F]-FESAHA), a PET radiotracer designed for the delineation of histone deacetylase expression in cancer.
Topics: Anilides; Animals; Biological Transport; Catalytic Domain; Cell Line, Tumor; Cell Proliferation; Dru | 2011 |
Preclinical evaluation of combined antineoplastic effect of DLC1 tumor suppressor protein and suberoylanilide hydroxamic acid on prostate cancer cells.
Topics: Animals; Antineoplastic Agents; BALB 3T3 Cells; Cell Line, Tumor; Combined Modality Therapy; DNA Met | 2012 |
Genistein cooperates with the histone deacetylase inhibitor vorinostat to induce cell death in prostate cancer cells.
Topics: Acetylation; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell | 2012 |
Vorinostat and bortezomib synergistically cause ubiquitinated protein accumulation in prostate cancer cells.
Topics: Animals; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferati | 2012 |
Modulation of radiation response by histone deacetylase inhibition.
Topics: Apoptosis; Caspases; Cell Division; Cell Survival; DNA Damage; Drug Screening Assays, Antitumor; Enz | 2005 |
Early clinical data and potential clinical utility of novel histone deacetylase inhibitors in prostate cancer.
Topics: Antineoplastic Agents; Benzamides; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; P | 2005 |
SAHA-sensitized prostate cancer cells to TNFalpha-related apoptosis-inducing ligand (TRAIL): mechanisms leading to synergistic apoptosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Caspases; | 2006 |
Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Cell Li | 2006 |
Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Carrier Proteins; Caspase Inhibitor | 2006 |
Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation.
Topics: Androgen Receptor Antagonists; Anilides; Anticarcinogenic Agents; Cell Cycle; Cell Death; Cell Proli | 2007 |
Synergistic activity of the histone deacetylase inhibitor suberoylanilide hydroxamic acid and the bisphosphonate zoledronic acid against prostate cancer cells in vitro.
Topics: Antineoplastic Agents; Benzamides; Cell Death; Cell Line, Tumor; Diphosphonates; Drug Screening Assa | 2007 |
OSU-HDAC42, a histone deacetylase inhibitor, blocks prostate tumor progression in the transgenic adenocarcinoma of the mouse prostate model.
Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Agents; Cell Line, Tumor; Enzyme Inhib | 2008 |
Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Cell Death; Cell Division; Enzyme Inhibitors; Growth Inhibitors; His | 2000 |